Allergan plc (AGN): Incrementally Cautious - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Mizuho Securities Remains Sidelined on Allergan (AGN) following 1Q Earnings; PT to $232
May 13, 2016 6:52 AM EDTMizuho Securities maintained a Neutral rating on Allergen (NYSE: AGN), and cut the price target to $232.00 (from $250.00), following the company's 1Q earnings report. AGN reported $3.8B in revenues and EPS of $3.04 vs. consensus estimates $3.95B and $3.00. Management reiterated its FY16 revenue guidance of... More
Allergan profit beats estimates, share buybacks planned
May 10, 2016 7:48 AM EDTBy Amrutha Penumudi and Ransdell Pierson
(Reuters) - Allergan Plc (NYSE: AGN), whose $160 billion merger with Pfizer Inc (NYSE: PFE) collapsed last month, reported a higher-than-expected quarterly profit and said it would buy back up to $10 billion in company stock, helping lift its shares 4 percent.
The Dublin drugmaker on Tuesday said the planned $40 billion sale of its generics business to Teva Pharmaceutical Industries (NYSE: TEVA) will close next month and that it will use $8 billion of the money to pay down... More
Allergan (AGN) Tops Q1 EPS by 1c
May 10, 2016 7:31 AM EDTAllergan (NYSE: AGN) reported Q1 EPS of $3.04, $0.01 better than the analyst estimate of $3.03. Revenue for the quarter came in at $3.8 billion versus the consensus estimate of $3.96 billion.
Allergan's full year 2016 continuing operations standalone estimates are based on management's current belief about prescription trends,... More
